戴兹通过调节AMPK/FOXO3a轴来改善洛瓦斯塔丁引起的肌肉缩
Keke Wang1, Hao Zeng2, Hua Yang3
1State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Chinese medicine
|December 31, 2024
概括
戴兹通过抑制AMPK/FOXO3a通路来缓解洛瓦斯塔丁诱导的肌肉缩. 这项研究突出了大idzein.
科学领域:
- 生物化学和分子生物学
- 药理学 药理学是指药理学的学科.
- 肌肉生理学 肌肉生理学
背景情况:
- 洛瓦斯塔丁是一种常见的降脂药物,可以导致骨肌肉缩.
- 豆衍生的异黄Daidzein显示出治疗肌肉疾病的潜力.
- 戴兹对洛瓦斯塔丁诱导的肌肉缩的疗效及其机制需要进一步研究.
研究的目的:
- 在体内和体外研究大吉素对洛瓦斯塔丁诱导的肌肉缩的保护作用.
- 阐明涉及AMPK/FOXO3a信号通路的潜在分子机制.
主要方法:
- 在小鼠,斑马鱼和C2C12神经管中利用了洛瓦斯塔丁诱导的肌肉缩模型.
- 使用siRNA,AMPK抑制剂 (化合物C) 和激动剂 (MK-3903) 来探索该机制.
- 通过免疫光学,H&E染色,西部斑点,qRT-PCR,ELISA用于肌酸酶和肌肉握力测试来评估肌肉缩.
主要成果:
- 在小鼠中,大吉素剂量依赖地缓解了肌肉缩,降低了血清肌酸激酶,并改善了握力.
- 戴泽因抑制了洛瓦斯塔丁诱导的AMPK激活,防止FOXO3a酸化和核转位.
- 这种机制抑制了与缩相关的蛋白Atrogin-1和MuRF-1的表达,其效果被AMPK抑制剂模仿.
结论:
- 戴兹通过阻断异常AMPK/FOXO3a激活,有效地改善了洛瓦斯塔丁诱导的骨肌缩.
- 这种作用抑制了下游肌肉消耗基因的表达.
- 戴兹通过AMPK/FOXO3a通路证明了对通过他类药物诱导的肌肉毒性进行管理的治疗潜力.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
465
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
465
01:21Satellite Stem Cells and Muscular Dystrophy
1.9K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.9K